The relevance of dopamine agonists in the treatment of depression;Die bedeutung von dopaminagonisten in der behandlung der depression

Neuropsychiatrie

Volumn 23, Issue 1, 2009, Pages 15-25

  Clausius, Nicola ^a   Born, Christoph ^a   Grunze, Heinz ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bupropion; Depression; Dopaminagonists; Pathophysiology

Indexed keywords

AMFEBUTAMONE; BROMOCRIPTINE; CABERGOLINE; CITALOPRAM; COCAINE; DEXAMPHETAMINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESCITALOPRAM; FLUOXETINE; HOMOVANILLIC ACID; LEVODOPA; LISURIDE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RESERPINE; ROPINIROLE; SERTRALINE; VENLAFAXINE; DOPAMINE; NORADRENALIN; SEROTONIN;

ANOREXIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DOPAMINERGIC SYSTEM; DRUG EFFICACY; FACIAL EXPRESSION; HUMAN; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; REVIEW; SEROTONINERGIC SYSTEM; SOMNOLENCE; SPEECH; BRAIN; NERVE CELL; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR DISORDER;

BRAIN; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DOPAMINE; DOPAMINE AGONISTS; HUMANS; NEURONS; NOREPINEPHRINE; PARKINSON DISEASE; PSYCHOMOTOR DISORDERS; SEROTONIN;

EID: 66149141023     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Alexopoulos G.S.: "The depression-executive dysfunction syndrome of late life": a specific target for D3 agonists? Am J Geriatr Psychiatry 9(1), 22-29 (2001).
2. Barone P., Scarzella L., Marconi R., Antonini A., Morgante L., Bracco F., Zappia M., Musch B.: Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 253(5), 601-607 (2006). (Pubitemid 43876990)
3. Berridge K.C.: The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191(3), 391-431 (2007).
4. Bouckoms A., Mangini L.: Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 29(2), 207-211 (1993).
5. Bouras N., Bridges P.K.: Bromocriptine in depression. Curr Med Res Opin 8(3), 150-153 (1982). (Pubitemid 12031645)
6. Bradberry C.W.: Cocaine sensitization and dopamine mediation of cue effects in rodents, monkeys, and humans: areas of agreement, disagreement, and implications for addiction. Psychopharmacology (Berl) 191(3), 705-717 (2007).
7. Buchwald B., Angersbach D., Jost W.H.: [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. Fortschr Neurol Psychiatr 75(4), 236-241 (2007).
8. Casey D.E.: Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65 Suppl 9:25-8., 25-28 (2004).
9. Cassano P., Lattanzi L., Fava M., Navari S., Battistini G., Abelli M., Cassano G.B.: Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 50(6), 357-360 (2005). (Pubitemid 43175517)
10. Chrzanowski W., Rousseau R., Hewett K., Gee M.D., Wightman D.S., Richard N., Modell J.G., Goodale E.P.: Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder. Eur Neuropsychopharmacol 16 Suppl 4, 315-316 (2006).
11. Clayton A.H.: Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin Pharmacother 8(4), 457-466 (2007).
12. Clayton A.H., Croft H.A., Horrigan J.P., Wightman D.S., Krishen A., Richard N.E., Modell J.G.: Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double- blind, placebo-controlled studies. J Clin Psychiatry 67(5), 736-746 (2006). (Pubitemid 43946180)
13. Clayton A.H., Thase M.E., Haight B.R., Harriett A.E., Richard N., Goodale E.P.: Comparision of bupropion extended release for the treatment of depression : a double-blind, multicentre trial. Eur Neuropsychopharmacol 16 Suppl 4, 316 (2006).
14. Coleman C.C., King B.R., Bolden- Watson C., Book M.J., Segraves R.T., Richard N., Ascher J., Batey S., Jamerson B., Metz A.: A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23(7), 1040-1058 (2001). (Pubitemid 32709626)
15. Coleman C.C., King B.R., Bolden- Watson C., Book M.J., Segraves R.T., Richard N., Ascher J., Batey S., Jamerson B., Metz A.: A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23(7), 1040-1058 (2001). (Pubitemid 32709626)
16. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L.: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11(2), 58-65 (2000). (Pubitemid 30228411)
17. Croft H., Settle E Jr, Houser T., Batey S.R., Donahue R.M., Ascher J.A.: A placebo- controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21(4), 643-658 (1999). (Pubitemid 29252088)
18. Croft H., Settle E Jr, Houser T., Batey S.R., Donahue R.M., Ascher J.A.: A placebo- controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21(4), 643-658 (1999). (Pubitemid 29252088)
19. Cummings J.L.: Psychosomatic aspects of movement disorders. Adv Psychosom Med 13:111-32., 111-132 (1985).
20. D'Aquila P.S., Collu M., Gessa G.L., Serra G.: The role of dopamine in the mechanism of action of antidepressant drugs. EUR J PHARMACOL 405(1-3), 365-373 (2000).
21. Devanand D.P., Bowers M.B., Jr., Hoffman F.J., Jr., Nelson J.C.: Elevated plasma homovanillic acid in depressed females with melancholia and psychosis. Psychiatry Res 15(1), 1-4 (1985). (Pubitemid 15076501)
22. Dhir A., Kulkarni S.K.: Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist. Brain Res Bull 74(1-3), 58-65 (2007). (Pubitemid 47187914)
23. Fabre L.F., Brodie H.K., Garver D., Zung W.W.: A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry 44(5 Pt 2), 88-94 (1983).
24. Fava M., Papakostas G.I., Petersen T., Mahal Y., Quitkin F., Stewart J., McGrath P.: Switching to bupropion in fluoxetineresistant major depressive disorder. Ann Clin Psychiatry 15(1), 17-22 (2003). (Pubitemid 36723637)
25. Featherstone R.E., Kapur S., Fletcher P.J.: The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31(8), 1556-1571 (2007). (Pubitemid 47625703)
26. Fedorova N.V., Chigir' I.P.: Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. Neurosci Behav Physiol 37(6), 539-546 (2007). (Pubitemid 47322123)
27. Feighner J.P., Gardner E.A., Johnston J.A., Batey S.R., Khayrallah M.A., Ascher J.A., Lineberry C.G.: Doubleblind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52(8), 329-335 (1991).
28. Feighner J.P., Gardner E.A., Johnston J.A., Batey S.R., Khayrallah M.A., Ascher J.A., Lineberry C.G.: Doubleblind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52(8), 329-335 (1991).
29. Feighner J.P., Gardner E.A., Johnston J.A., Batey S.R., Khayrallah M.A., Ascher J.A., Lineberry C.G.: Doubleblind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52(8), 329-335 (1991).
30. Fleminger S.: Control of simultaneous movements distinguishes depressive motor retardation from Parkinson's disease and neuroleptic parkinsonism. Brain 115(Pt 5), 1459-1480 (1992).
31. Goldberg J.F., Burdick K.E., Endick C.J.: Preliminary randomized, doubleblind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression 4807. Am J Psychiatry 161(3), 564-566 (2004). (Pubitemid 38326114)
32. Goodwin F.K., Post R.M., Dunner D.L., Gordon E.K.: Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique. Am J Psychiatry 130(1), 73-79 (1973).
33. Hubbard R.C., Lewis S., West J.C., Smith C., Godfrey C., Smeeth L., Farrington P., Britton J.: Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 60, 848-850 (2005). (Pubitemid 41475213)
34. Izumi T., Inoue T., Kitagawa N., Nishi N., Shimanaka S., Takahashi Y., Kusumi I., Odagaki Y., Denda K., Ohmori T., Koyama T.: Open pergolide treatment of tricyclic and heterocyclic antidepressant- resistant depression. J Affect Disord 61(1-2), 127-132 (2000).
35. Kapur S., Mann J.J.: Role of the dopaminergic system in depression. Biol Psychiatry 32(1), 1-17 (1992).
36. Kavoussi R.J., Segraves R.T., Hughes A.R., Ascher J.A., Johnston J.A.: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58(12), 532-537 (1997). (Pubitemid 28100273)
37. Kavoussi R.J., Segraves R.T., Hughes A.R., Ascher J.A., Johnston J.A.: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58(12), 532-537 (1997). (Pubitemid 28100273)
38. Kennedy S.H., Fulton K.A., Bagby R.M., Greene A.L., Cohen N.L., Rafi-Tari S.: Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 51(4), 234-242 (2006).
39. Kilbourn M.R., Sherman P.S., Pisani T.: Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 216(1), 109-112 (1992).
40. Korf J., van Praag H.M.: Retarded depression and the dopamine metabolism. Psychopharmacologia 19(2), 199-203 (1971).
41. Laasonen-Balk T., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Lehtonen J., Tiihonen J.: Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 144(3), 282-285 (1999). (Pubitemid 29307281)
42. Lemke M.R.: Motorische Phänomene der Depression. Nervenarzt 70(7), 600-612 (1999).
43. Lemke MR. Dopaminagonisten. In: Bauer M, Berghoefer A, Adli M, editors. Akute und therapieresistente Depressionen, Pharmakotherapie - Psychotherapie - Innovationen. Heidelberg: Springer Medizin Verlag, 2005: 321-328.
44. Lemke MR. Motion und Emotion. Morbus Parkinson und Depression. In: Förstl H, editor. Frontalhirn,Funktionen und Erkrankungen. Heidelberg: Springer Medizin Verlag, 2005: 178-191.
45. Lemke M.R.: Dopaminagonisten als Antidepressiva : Experimentelle und klinische Befunde. Nervenarzt 78(1), 31-38 (2007).
46. Lemke M.R., Puhl P., Koethe N., Winkler T.: Psychomotor retardation and anhedonia in depression. Acta Psychiatr Scand 99(4), 252-256 (1999). (Pubitemid 29155592)
47. Lemke M.R., Wendorff T., Mieth B., Buhl K., Linnemann M.: Spatiotemporal gait patterns during over ground locomotion in major depression compared with healthy controls. J Psychiatr Res 34(4-5), 277-283 (2000).
48. Lineberry C.G., Johnston J.A., Raymond R.N., Samara B., Feighner J.P., Harto N.E., Granacher R.P., Jr., Weisler R.H., Carman J.S., Boyer W.F.: A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 51(5), 194-199 (1990). (Pubitemid 20159096)
49. Markianos M., Alevizos B., Hatzimanolis J., Stefanis C.: Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients. Psychiatry Res 52(3), 259-264 (1994). (Pubitemid 24225423)
50. Mattes J.A.: Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann Clin Psychiatry 9(2), 87-88 (1997).
51. Mayeux R.: Depression in the patient with Parkinson's disease. J Clin Psychiatry 51 Suppl:20-3; discussion 24-5., 20-23 (1990).
52. McKinney W.T., Jr., Kane F.J., Jr.: Depression with the use of alpha-methyldopa. Am J Psychiatry 124(1), 80-81 (1967).
53. Mergl R., Juckel G., Rihl J., Henkel V., Karner M., Tigges P., Schroter A., Hegerl U.: Kinematical analysis of handwriting movements in depressed patients. Acta Psychiatr Scand 109(5), 383-391 (2004). (Pubitemid 38491284)
54. Meyer J.H., Goulding V.S., Wilson A.A., Hussey D., Christensen B.K., Houle S.: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 163(1), 102-105 (2002). (Pubitemid 34985318)
55. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., Minifie C., Houle S., Hussey D., Kennedy S.H.: Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12(18), 4121-4125 (2001). (Pubitemid 33152464)
56. Montgomery S.A.: Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 59(12), 1435-1440 (2005).
57. Nestler E.J., Carlezon W.A., Jr.: The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59(12), 1151-1159 (2006).
58. Papakostas G.I.: Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 16(6), 391-402 (2006).
59. Papakostas G.I., Nutt D.J., Hallett L.A., Tucker V.L., Krishen A., Fava M.: Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 60(12), 1350-1355 (2006). (Pubitemid 44838537)
60. Papakostas G.I., Trivedi M.H., Alpert J.E., Seifert C.A., Krishen A., Goodale E.P., Tucker V.L.: Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res . (2007).
61. Papeschi R., McClure D.J.: Homovanillic and 5-hydroxyindoleacetic acid in cerebrospinal fluid of depressed patients. Arch Gen Psychiatry 25(4), 354-358 (1971).
62. Perugi G., Toni C., Ruffolo G., Frare F., Akiskal H.: Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 34(4), 137-141 (2001). (Pubitemid 32701763)
63. Praag H.M., Korf J., Lakke J.P.W.F., Schut T.: Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. Psychol Med 5(2), 138-146 (1975).
64. Rampello L., Nicoletti G., Raffaele R.: Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand 84(6), 552-554 (1991).
65. Randrup A, Munncvad I, Fog R, Gerlach J, Molander L, Kjellberg B et al. Mania, depression, and brain dopamine. In: Essman WB, Valzelli L, editors. Current developments in psychopharmacology. New York: Spectrum Publications, 1975: 207-229.
66. Reichmann H., Brecht H.M., Kraus P.H., Lemke M.R.: Pramipexol bei der Parkinson-Krankheit.Ergebnisse einer Anwendungsbeobachtung. Nervenarzt 73(8), 745-750 (2002).
67. Rektorova I., Rektor I., Bares M., Dostal V., Ehler E., Fanfrdlova Z., Fiedler J., Klajblova H., Kulist'ak P., Ressner P., Svatova J., Urbanek K., Veliskova J.: Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10(4), 399-406 (2003).
68. Rogers D.C., Costall B., Domeney A.M., Gerrard P.A., Greener M., Kelly M.E., Hagan J.J., Hunter A.J.: Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl) 151(1), 91-97 (2000). (Pubitemid 30639845)
69. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M.: Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry 163(11), 1905-1917 (2006). (Pubitemid 44807782)
70. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M.: Bupropion- SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354(12), 1231-1242 (2006).
71. Sadock BJ, Saddock VA. The Brain and Behavior, Neurophysiology and Neurochemistry. In: Sadock BJ, Saddock VA, editors. Kaplan & Sadock's Synopsis of Psychiatry, Behavioral Sciences / Clinical Psychiatry. Philadelphia: Lippincott Williams & Wilk, 2007: 94-110.
72. Salamone J.D.: Functions of mesolimbic dopamine: changing concepts and shifting paradigms. Psychopharmacology (Berl) 191(3), 389 (2007).
73. Sarchiapone M., Carli V., Camardese G., Cuomo C., Di G.D., Calcagni M.L., Focacci C., De R.S.: Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 147(2-3), 243-248 (2006). (Pubitemid 44397469)
74. Schatzberg A.F., Rothschild A.J., Langlais P.J., Bird E.D., Cole J.O.: A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19(1), 57-64 (1985). (Pubitemid 15133225)
75. Schildkraut J.J.: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122(5), 509-522 (1965).
76. Settle E.C.: Bupropion sustained release: side effect profile. J Clin Psychiatry 59 Suppl 4, 32-36 (1998).
77. Shaw K.M., Lees A.J., Stern G.M.: The impact of treatment with levodopa on Parkinson's disease. Q J Med 49(195), 283-293 (1980). (Pubitemid 11240660)
78. Sher L, Mann JJ. Psychiatric Pathophysiology: Mood Disorders. In: Tasman A, Kay J, Lieberman JA, editors. Psychiatry. Chichester: John Wiley & Sons Ltd., 2003: 300-315.
79. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A.: Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15(4), 669-677 (2000). (Pubitemid 30479619)
80. Stahl SM. Essential Psychopharmacology: Neuroscientific basis and practical applications. 2nd ed. Cambridge: Cambridge University Press, 2004.
81. Sweeney D., Nelson C., Bowers M., Maas J., Heninger G.: Delusional versus nondelusional depression: Neurochemical differences. Lancet 2(8080), 100-101 (1978).
82. Thase M.E., Clayton A.H., Haight B.R., Thompson A.H., Modell J.G., Johnston J.A.: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 26(5), 482-488 (2006). (Pubitemid 44401468)
83. Thase M.E., Clayton A.H., Haight B.R., Thompson A.H., Modell J.G., Johnston J.A.: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 26(5), 482-488 (2006). (Pubitemid 44401468)
84. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., VanMeter S., Harriett A.E., Wang Y.: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66(8), 974-981 (2005). (Pubitemid 41191788)
85. Ulrich G., Harms K.: A video analysis of the non-verbal behaviour of depressed patients before and after treatment. J Affect Disord 9(1), 63-67 (1985). (Pubitemid 15068949)
86. Vestergaard P., Sorensen T., Hoppe E., Rafaelsen O.J., Yates C.M., Nicolaou N.: Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand 58(1), 88-96 (1978). (Pubitemid 8397271)
87. Weihs K.L., Houser T.L., Batey S.R., Ascher J.A., Bolden-Watson C., Donahue R.M., Metz A.: Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 51(9), 753-761 (2002). (Pubitemid 34450811)
88. Weihs K.L., Settle E.C., Jr., Batey S.R., Houser T.L., Donahue R.M., Ascher J.A.: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61(3), 196-202 (2000). (Pubitemid 30214516)
89. Weihs K.L., Settle E.C., Jr., Batey S.R., Houser T.L., Donahue R.M., Ascher J.A.: Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61(3), 196-202 (2000). (Pubitemid 30214516)
90. Wells B.G., Marken P.A.: Bromocriptine in treatment of depression. DICP 23(7-8), 600-602 (1989). (Pubitemid 19189952)
91. Whitehead C., Moss S., Cardno A., Lewis G.: Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev(2), CD002305 (2002).
92. Willner P.: Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res 287(3), 237-246 (1983).
93. Winkler T., Buhl K., Linnemann M., Mieth B., Stolze H., Lemke M.R.: Alterations of gait parameters in depression. Eur Arch Psychiatry Clin Neurosci 248 Suppl, 126 (1998).
94. Zarate C.A., Jr., Payne J.L., Singh J., Quiroz J.A., Luckenbaugh D.A., Denicoff K.D., Charney D.S., Manji H.K.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study 4806. Biol Psychiatry 56(1), 54-60 (2004). (Pubitemid 38813406)